Curida Holding has announced a significant growth investment from Signet Healthcare Partners, a New York-based healthcare private equity firm together with existing shareholders, Canica, Investinor, Klaveness Marine and Farvatn Private Equity.

This investment will enable Curida to accelerate its expansion plans, including enhancing facility capabilities and growing its industry position, it states. The total investment is in the range of NOK 230 million – NOK 260 million, but investment details has not been officially disclosed.

The total investment is in the range of NOK 230 million – NOK 260 million, but investment details has not been officially disclosed.”

In conjunction with Signet’s investment, Signet is joining the Board of Directors, and Ole J. Dahlberg has been appointed as Chairman of the Board.

“We are very pleased to welcome Signet in as a significant shareholder in Curida. Signet brings strong relevant industry experience and a track record of CDMO investing. We are excited by the opportunity to further accelerate growth and improve products for our pharma and biotech customers in their work to deliver medicines and therapeutics to benefit patients. On behalf of the board, I want to thank Per Thoresen, who has been acting Chairman and for his valuable contributions to Curida over the past 9 years,” says Dahlberg.

New CEO

The Board has appointed Anders Larsson, the company’s Chief Operating Officer, as CEO, effective May 1st 2024. Larsson comes with extensive experience in management, operations, and strategic development from the pharma industry. His former roles include CEO in Boots Pharmacies/Alliance Healthcare in Norway (Cencora). In addition, Larsson has held multiple management roles in the food & beverage industry with Orkla and Carlsberg. Larsson holds a MSc in Chemical Engineering from Chalmers University and Imperial College and a BSc in finance from Gothenburg University.

Photo of Ole Jesper Dahlberg and Anders Larsson: Curida